Michael Harnois

Quebec, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.

MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.

Journal: Blood advances

Published: October 08, 2025

Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study.

Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study.

Journal: Blood cancer journal

Published: November 11, 2024

Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact-a study of 784 patients from the Quebec MPN research group.

Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact-a study of 784 patients from the Quebec MPN research group.

Journal: Blood cancer journal

Published: October 06, 2024

Fibrosis and treatment-free remission in chronic myeloid leukaemia.

Fibrosis and treatment-free remission in chronic myeloid leukaemia.

Journal: British journal of haematology

Published: September 16, 2024

Perioperative outcomes in patients with myeloproliferative neoplasms: a multicentric analysis of 354 surgical procedures.

Perioperative outcomes in patients with myeloproliferative neoplasms: a multicentric analysis of 354 surgical procedures.

Journal: Blood vessels, thrombosis & hemostasis

Published: June 24, 2024

CALR mutation burden in essential thrombocythemia and disease outcome.

CALR mutation burden in essential thrombocythemia and disease outcome.

Journal: Blood

Published: December 04, 2023

Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group.

Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group.

Journal: American journal of hematology

Published: March 07, 2021

Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera.

Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera.

Journal: Blood cancer journal

Published: December 14, 2020

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Journal: Haematologica

Published: January 12, 2019

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.

Journal: Cancer

Published: June 06, 2018

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.

Journal: American journal of hematology

Published: June 20, 2017

Impaired interferon-alpha production by plasmacytoid dendritic cells after cord blood transplantation in children: implication for post-transplantation toll-like receptor ligand-based immunotherapy.

Impaired interferon-alpha production by plasmacytoid dendritic cells after cord blood transplantation in children: implication for post-transplantation toll-like receptor ligand-based immunotherapy.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Published: February 13, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026